Literature DB >> 6288509

Isosorbide dinitrate and nifedipine treatment of achalasia: a clinical, manometric and radionuclide evaluation.

M Gelfond, P Rozen, T Gilat.   

Abstract

The effects of sublingual isosorbide dinitrate (5 mg) and nifedipine (20 mg) were compared in 15 patients with achalasia. The parameters examined included the manometric measurement of the lower esophageal sphincter pressure, the radionuclide assessment of esophageal emptying and the clinical response. The mean basal lower esophageal sphincter pressure fell significantly after both drugs (p less than 0.01), with a maximum fall of 63.5% 10 min after receiving isosorbide dinitrate, but by only 46.7% 30 min after nifedipine. The esophageal radionuclide test meal retention was significantly less (p less than 0.01) only after receiving isosorbide dinitrate. The drug improved initial esophageal emptying by its effect on the lower esophageal sphincter and by relieving the test meal hold-up noted to occur at the junction of the upper and midesophagus. Eight patients cleared their test meal within 10 min after isosorbide dinitrate administration while only two did so after nifedipine. Subjectively, 13 patients had their dysphagia relieved by isosorbide dinitrate and 8 by nifedipine. However, this relief was not confirmed in 4 patients by the radionuclide study and they, as well as the other 3 patients who did not respond to therapy, were referred to pneumatic dilatation. Side effects were more prominent after nitrates. Three of the patients are currently receiving nifedipine and 5 patients received isosorbide dinitrate therapy for 8-14 mo. The radionuclide test meal is currently the best way of objectively evaluating drug therapy in patients with achalasia. Isosorbide dinitrate is more effective than nifedipine in relieving their symptoms.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288509

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  61 in total

Review 1.  An overview of the role of calcium antagonists in the treatment of achalasia and diffuse oesophageal spasm.

Authors:  T P Short; E Thomas
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 2.  Pharmacotherapy for the management of achalasia: Current status, challenges and future directions.

Authors:  Ammar Nassri; Zeeshan Ramzan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

3.  Treatment of esophageal achalasia with Heller myotomy: retrospective evaluation of patient satisfaction and disease-specific quality of life.

Authors:  Yen Dang; Dale Mercer
Journal:  Can J Surg       Date:  2006-08       Impact factor: 2.089

Review 4.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

5.  On drugs and dilators for achalasia.

Authors:  M Traube
Journal:  Dig Dis Sci       Date:  1991-03       Impact factor: 3.199

6.  Guess the case from the ochsner archives.

Authors:  David J Licini; William S Richardson
Journal:  Ochsner J       Date:  2008

Review 7.  Hirschprung's disease.

Authors:  P B Sullivan
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

Review 8.  Expert consensus document: Advances in the management of oesophageal motility disorders in the era of high-resolution manometry: a focus on achalasia syndromes.

Authors:  Peter J Kahrilas; Albert J Bredenoord; Mark Fox; C Prakash Gyawali; Sabine Roman; André J P M Smout; John E Pandolfino
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-27       Impact factor: 46.802

9.  An Overview of Achalasia and Its Subtypes.

Authors:  Dhyanesh A Patel; Brian M Lappas; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-07

Review 10.  Primary oesophageal motility disorders. Current therapeutic concepts.

Authors:  M Traube; R W McCallum
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.